Clinical Trials: Lowereing A1C, Weight Change & CV Data

See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

PDF) Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

Clinical Trials: Lowereing A1C, Weight Change & CV Data

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

Blood pressure lowering effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA)

A randomized clinical trial comparing low-fat with precision nutrition–based diets for weight loss: impact on glycemic variability and HbA1c - The American Journal of Clinical Nutrition

Hemoglobin A1c Reduction and CV Risk Improvement: Correlation, Causation and Clinical Recommendations

Statins may increase diabetes, but benefit still outweighs risk

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes, Cardiovascular Diabetology

Incretins: How we got here, where we're at and what is coming next - DiabetesontheNet

A Review of the Glycemia Reduction Approaches in Diabetes (GRADE) Study: Comparing the Effectiveness of Type 2 Diabetes Medications